Skip to Main Content

Adamas Pharmaceuticals (ADMS) had five minutes on Thursday night to feel good about its first U.S. drug approval before sniping over pricing kicked in.

The FDA approved the new Adamas product, to be marketed under the brand name Gocovri, to reduce dyskinesia (involuntary movements) experienced by some Parkinson’s disease patients on levodopa therapy. Adamas noted Thursday that Gocovri is the first and only FDA-approved medicine for this indication, but the claim comes with an asterisk.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • The answer is no it should not. I wonder if it is possible to take the original in divided doses?

Comments are closed.